Prevention of preeclampsia with low-molecular-weight heparins
Serov V.N., Pasman N.M., Pismak M.A., Vagner Yu.N.
Preeclampsia is a complication of pregnancy that belongs to the group of great obstetrical syndromes. It is one of the leading causes of maternal and perinatal morbidity and mortality. Therefore, the prevention of this condition is a matter of significant concern. If a pregnant woman is at high risk of preeclampsia, she is administered acetylsalicylic acid from 12 to 36 weeks. This is currently the only approved method for preventing preeclampsia, apart from calcium supplementation for patients who do not consume enough calcium. Unfortunately, these methods of prevention have limited effectiveness. One of the most promising methods for preventing preeclampsia is the use of low-molecular-weight heparins.
Conclusion: The studied data on the changes in the hemostasis system in pre-eclampsia, the points of influence of low-molecular-weight heparins on the pathogenesis and etiology of preeclampsia, and their effectiveness in preventing this complication of pregnancy may provide a basis for further research into the effectiveness of low-molecular-weight heparins in preventing preeclampsia and for introducing this method into routine clinical practice.
Authors' contributions: Serov V.N. – editing the article; Pasman N.M. – editing the article, analysis of the presented literary data; Pismak M.A. – collection and analysis of literary data, writing the article; Vagner Yu.N. – editing the article, analysis of the presented literary data.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Serov V.N., Pasman N.M., Pismak M.A., Vagner Yu.N.
Prevention of preeclampsia with low-molecular-weight heparins.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (1): 12-17 (in Russian)
https://dx.doi.org/10.18565/aig.2024.234
Keywords
preeclampsia
pregnancy
haemostasis system
low-molecular-weight heparins
References
- Poon L.C., Shennan A., Hyett J.A., Kapur A., Hadar E, Divakar H. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet. 2019; 145(1): 1-33. https://dx.doi.org/10.1002/ijgo.12802.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. М.; 2021. 81с. [Ministry of Health of the Russian Federation. Clinical guidelines. Preeclampsia. Eclampsia. Edema, proteinuria and hypertensive disorders during pregnancy, labor and the postpartum period. Moscow; 2021. 81 p. (in Russian)].
- Jung E., Romero R., Yeo L., Gomez-Lopez N., Chaemsaithong P., Jaovisidha A. et al. The etiology of preeclampsia. Am. J. Obstet. Gynecol. 2022; 226(2): 844-66. https://dx.doi.org/10.1016/j.ajog.2021.11.1356.
- Staff A.C., Fjeldstad H.E., Fosheim I.K., Moe K., Turowski G., Johnsen G.M. et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am. J. Obstet. Gynecol. 2022; 226(2): 895-906. https://dx.doi.org/10.1016/j.ajog.2020.09.026.
- Zhang L., Liu J., Feng X., Lash G.E. Unraveling the mysteries of spiral artery remodeling. Placenta. 2023; 141: 51-6. https://dx.doi.org/10.1016/j.placenta.2023.05.013.
- Phipps E.A., Thadhani R., Benzing T., Karumanchi S.A. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat. Rev. Nephrol. 2019; 15(5): 275-89. https://dx.doi.org/10.1038/s41581-019-0119-6.
- Christopher W. I., Rachel S., Indranee R., Alan T.N., Suzanne O. Preeclampsia – pathophysiology and clinical presentations. JACC State-of-the-Art Review. 2020; 76(14): 1690-702. https://dx.doi.org/10.1016/j.jacc.2020.08.014.
- Schuermans A., Truong B., Ardissino M., Bhukar R., Slob E.A.W., Nakao T. et al. Genetic associations of circulating cardiovascular proteins with gestational hypertension and preeclampsia. JAMA Cardiol. 2024; 9(3): 209-20. https://dx.doi.org/10.1001/jamacardio.2023.4994.
- Rana S., Lemoine E., Granger J.P., Karumanchi S.A. Preeclampsia: pathophysiology, challenges, and perspectives. Circ. Res. 2019; 124(7):1094-112. https://dx.doi.org/10.1161/CIRCRESAHA.118.313276.
- Han C., Chen Y.Y., Dong J.F. Prothrombotic state associated with preeclampsia. Curr. Opin. Hematol. 2021; 28(5): 323-30. https://dx.doi.org/10.1097/MOH.0000000000000678.
- Han C., Huang P., Lyu M., Dong J. Oxidative stress and preeclampsia-associated prothrombotic state. Antioxidants (Basel). 2020; 9(11): 1139. https://dx.doi.org/10.3390/antiox9111139.
- Agbani E.O., Skeith L., Lee A. Preeclampsia: Platelet procoagulant membrane dynamics and critical biomarkers. Res. Pract. Thromb. Haemost. 2023; 7(2): 100075. https://dx.doi.org/10.1016/j.rpth.2023.100075.
- Scheres L.J.J., Lijfering W.M., Groenewegen N.F.M., Koole S., de Groot C.J.M., Middeldorp S. et al. Hypertensive complications of pregnancy and risk of venous thromboembolism. Hypertension. 2020; 75(3): 781-7. https://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14280.
- Duley L., Meher S., Hunter K.E., Seidler A.L., Askie L.M. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. 2019; 2019(10): CD004659. https://dx.doi.org/10.1002/14651858.CD004659.pub3.
- Brownfoot F., Rolnik D.L. Prevention of preeclampsia. Best Pract. Res. Clin. Obstet Gynaecol. 2024; 93: 102481. https://dx.doi.org/10.1016/j.bpobgyn.2024.102481.
- Kupka E., Roberts J.M., Mahdy Z.A., Escudero C., Bergman L., De Oliveira L.; Global Pregnancy Collaboration. Aspirin for preeclampsia prevention in low- and middle-income countries: mind the gaps. AJOG Glob. Rep. 2024; 4(2): 100352. https://dx.doi.org/10.1016/j.xagr.2024.100352.
- Hofmeyr G.J., Lawrie T.A., Atallah A.N., Torloni M.R. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 2018; 10(10): CD001059. https://dx.doi.org/10.1002/14651858.CD001059.pub5.
- Hao C., Sun M., Wang H., Zhang L., Wang W. Low molecular weight heparins and their clinical applications. Prog. Mol. Biol. Transl. Sci. 2019; 163: 21-39. https://dx.doi.org/10.1016/bs.pmbts.2019.02.003.
- Министерство здравоохранения Российской федерации. Клинические рекомендации. Венозные осложнения во время беременности и послеродовом периоде. Акушерская тромбоэмболия. М.; 2021. 85 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Venous complications during pregnancy and the postpartum period. Obstetric thromboembolism. Moscow; 2021. 85 p. (in Russian)].
- Zullino S., Clemenza S., Mecacci F., Petraglia F. Low Molecular Weight Heparins (LMWH) and implications along pregnancy: a focus on the placenta. Reprod. Sci. 2022; 29(5): 1414-23. https://dx.doi.org/10.1007/s43032-021-00678-0.
- Jacobson B., Rambiritch V., Paek D., Sayre T., Naidoo P., Shan J., Leisegang R. Safety and efficacy of enoxaparin in pregnancy: a systematic review and meta-analysis. Adv. Ther. 2020; (1): 27-40. https://dx.doi.org/10.1007/s12325-019-01124-z.
- Novak P., Novak A., Šabović M., Kozak M. Prophylactic dose of dalteparin in pregnant women with history of venous thromboembolisms and/or thrombophilia: real-world data. Angiology. 2023; 74(8): 783-9. https://dx.doi.org/10.1177/00033197221126244.
- Groom K.M., McCowan L.M., Mackay L.K., Lee A.C., Said J.M., Kane S.C. et al.; Enoxaparin for Prevention of Preeclampsia and Intrauterine Growth Restriction Trial Investigator Group. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am. J. Obstet. Gynecol. 2017; 216(3): 296e1-e14. https://dx.doi.org/10.1016/j.ajog.2017.01.014.
- Lamont M.C., McDermott C., Thomson A.J., Greer I.A. United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: evidence and rationale. Semin. Perinatol. 2019; 43(4): 222-8. https://dx.doi.org/10.1053/j.semperi.2019.03.008.
- Cruz-Lemini M., Vázquez J.C., Ullmo J., Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2022; 226(2S): S1126-S1144.e17. https://dx.doi.org/10.1016/j.ajog.2020.11.006.
Received 16.09.2024
Accepted 25.12.2024
About the Authors
Vladimir N. Serov, Dr. Med. Sci., Academician of the RAS, Professor, Chief Researcher, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4, +7(495)438-72-87, v_serov@oparina4.ru, http://orcid.org/0000-0001-6640-1235Natalia M. Pasman, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology of the Institute of Medicine and Medical Technologies, Faculty of Medicine and Psychology, Novosibirsk State University, 630090, Russia, Novosibirsk, Pirogov str., 2, +7(913)916-25-91, nmpasman@gmail.com,
https://orcid.org/0000-0002-6095-1954
Maria A. Pismak, student at the Department of Obstetrics and Gynecology of the Institute of Medicine and Medical Technologies, Faculty of Medicine and Psychology, Novosibirsk State University, 630090, Russia, Novosibirsk, Pirogov str., 2, +7(961)716-97-19, m.pismak@g.nsu.ru
Yuliya N. Vagner, PhD, Associate Professor at the Department of Internal Diseases of the Institute of Medicine and Medical Technologies, Faculty of Medicine and Psychology, Novosibirsk State University, 630090, Russia, Novosibirsk, Pirogov str., 2, +7(903)902-69-82, skvortsova-1963@bk.ru
Corresponding author: Maria A. Pismak, m.pismak@g.nsu.ru
Similar Articles
